Axsome Therapeutics - AXSM Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued 12 month target prices for Axsome Therapeutics' stock. Their AXSM share price forecasts range from $75.00 to $210.00. On average, they expect the company's stock price to reach $108.15 in the next year. This suggests a possible upside of 45.2% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.

Axsome Therapeutics' stock was trading at $77.13 at the beginning of the year. Since then, AXSM stock has decreased by 3.4% and is now trading at $74.48.
View the best growth stocks for 2023 here.

Axsome Therapeutics saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 7,940,000 shares, an increase of 5.2% from the December 31st total of 7,550,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 5.9 days. Currently, 22.4% of the shares of the company are short sold.
View Axsome Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AXSM earnings forecast.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings data on Monday, November, 7th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.07. The firm earned $16.85 million during the quarter, compared to the consensus estimate of $16.59 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.22%), Hennion & Walsh Asset Management Inc. (0.21%), Lindbrook Capital LLC (0.19%), Moody Aldrich Partners LLC (0.12%), Baldwin Brothers LLC MA (0.11%) and New York State Common Retirement Fund (0.07%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends.

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXSM stock can currently be purchased for approximately $74.48.

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.23 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis.

The company employs 108 workers across the globe.

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.